Usefulness of Vaspin Marker and C-reactive Protein in Assessment of the Severity of Psoriasis | ||||
| Egyptian Journal of Medical Research | ||||
| Article 5, Volume 3, Issue 1, January 2022, Page 57-67 PDF (437.17 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejmr.2022.216270 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Aya Emad Eldin Mohamed Sadek1; Abd El-Aziz El Rifaie2; Laila Ahmed Rashed3; Rehab Mohamed Naguib2 | ||||
| 1Dermatology department Elwasta central hospital, Ministry of health | ||||
| 2Dermatology department, Faculty of Medicine, Beni-Suef University, Egypt | ||||
| 3Biochemistry department, Faculty of Medicine, Cairo University, Egypt. | ||||
| Abstract | ||||
| This study aims to study the level of Vaspin and CRP in the serum of psoriatic patients as compared to normal control persons and to correlate their levels with the severity of the disease. Methods: 30 psoriasis patients as cases vs 30 normal patients as control were tested for CRP and Vaspin correlating the results with the Psoriasis Severity Index PSI. Results: There was a highly statistically significant difference between cases and controls regarding their VASPIN and CRP levels (P-value<0.001). in cases there was a significant positive moderate linear correlation between CRP and PASI. There was a significant strong negative linear correlation between the VASPIN and the PASI score (P-value=0.009), showed that at a cut off 75.6 of vaspin predicted that the patient had no psoriasis with 100% sensitivity and 75.6% specificity. Conclusions: CRP and Vaspin could be used as markers to assess the severity of the disease and treatment response. | ||||
| Keywords | ||||
| Psoriasis; Vaspin; CRP | ||||
| References | ||||
|
1- Roberson, E.D., Bowcock, A. M. (2010). Psoriasis genetics: breaking the barrier. Trends in Genetics, 26(9), 415-423.
2- Nickoloff, B. J., & Nestle, F. O. (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. The Journal of clinical investigation, 113(12), 1664-1675.
3- Lui, H. and Mamelak, A.J. (2009): Psoraisis. Emedicine. Medscape.com.
4- Finlay, A.Y. (2005). Current severe psoriasis and the rule of tens. British Journal of Dermatology, 152(5), 861-867.
5- Mehta, N. N., Li, K., Szapary, P., Krueger, J., & Brodmerkel, C. (2013). Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. Journal of translational medicine, 11(1), 1-8.
6- Du Clos, T. W., & Mold, C. (2004). C-reactive protein. Immunologic research, 30(3), 261-277.
7- Lago, F., Dieguez, C., Gómez-Reino, J., & Gualillo, O. (2007). Adipokines as emerging mediators of immune response and inflammation. Nature clinical practice Rheumatology, 3(12), 716-724.
8- Heiker, J. T. (2014). Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. Journal of Peptide Science, 20(5), 299-306.
9- Youn, B. S., Klöting, N., Kratzsch, J., Lee, N., Park, J. W., Song, E. S., ... & Blüher, M. (2008). Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 57(2), 372-377.
10- Gökalp, H. (2018). Effect of psoriasis severity on inflammation parameters: controlled study. Turk J Dermatol, 52.
11- Serwin, A.B., Wasowicz, W., & Chodynicka, B. (2006). Selenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition, 22(9), 860-864.
12- Uysal, S., Yilmaz, F. M., Karatoprak, K., Artuz, F., & Cumbul, N. U. (2014). The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci, 18(22), 3453-8.
13- Jain, V. K., & Lal, H. (2011). C-reactive protein and uric acid levels in patients with psoriasis. Indian journal of clinical biochemistry, 26(3), 309-311.
14- Biljan, D., Šitum, M., Kostović, K., Batinac, T., & Matišić, D. (2009). Acute phase proteins in psoriasis. Collegium antropologicum, 33(1), 83-86.
15- Coimbra, S., Oliveira, H., Reis, F., Belo, L., Rocha, S., Quintanilha, A& Santos‐Silva, A. (2010). C‐reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. Journal of the European Academy of Dermatology and Venereology, 24(7), 789-796.
16- Chodorowska, G., Wojnowska, D., & Juszkiewicz‐Borowiec, M. (2004). C‐reactive protein and α2‐macroglobulin plasma activity in medium–severe and severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 18(2), 180-183.
17- Strober, B., Teller, C., Yamauchi, P., Miller, J. L., Hooper, M., Yang, Y. C., & Dann, F. (2008). Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal of Dermatology, 159(2), 322-330.
18- Kanelleas, A., Liapi, C., Katoulis, A., Stavropoulos, P., Avgerinou, G., Georgala, S & Katsambas, A. (2011). The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clinical and Experimental Dermatology: Clinical dermatology, 36(8), 845-850.
19- Saalbach, A., Tremel, J., Herbert, D., Schwede, K., Wandel, E., Schirmer, C., ... & Simon, J. C. (2016). Anti-inflammatory action of keratinocyte-derived vaspin: relevance for the pathogenesis of psoriasis. The American journal of pathology, 186(3), 639-651.
20- Ataseven, A., & Kesli, R. (2014). Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 151(3), 244-250. | ||||
|
Statistics Article View: 326 PDF Download: 159 |
||||
